DNDi E-news
July 2015  |   View Online

The FACT project: a successful approach to solving public health needs


Viewpoint by Jean-René Kiechel, Senior Pharma Advisor & Product manager, DNDi


The beginning of the current millennium saw a radical change in the way malaria was treated. In 2001, in response to rising chloroquine resistance, the WHO recommended replacing this monotherapy with artemisinin-based combination therapies, known as ACTs. The Drugs for Neglected Diseases Working Group of the MSF Access Campaign and WHO-TDR came together with other experts and stakeholders from both non-endemic and endemic countries to form the Fixed-Dose Combination Therapies (FACT) consortium in 2002, with projects subsequently transferred to DNDi when it was established in 2003. »

Drug Discovery Booster launched to accelerate R&D for most neglected diseases


In a groundbreaking experiment, DNDi launches its first cross-company project to accelerate and cut the cost of early stage drug discovery for leishmaniasis and Chagas disease, with Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca Ltd. The Japanese Global Health Innovative Technology Fund (GHIT) is supporting this project. »

Global health leaders call for a biomedical innovation fund and mechanism for global public health needs


Facing the fragmentation of recent proposals to tackle R&D gaps for antimicrobial resistance, emerging infectious diseases such as Ebola, and other neglected diseases, a group of experts including MSF and DNDi jointly published a call for an umbrella framework to tackle chronic under-investment in R&D. »

DNDi ‘passes the ball’ to MMV in a transfer of two antimalarials


Two fixed-dose artemisinin combination therapies (ACTs) developed by DNDi  and partners, ASAQ FDC and ASMQ FDC, will now be managed by MMV’s Access and Product Management team to help maximize their public health impact. »

US FDA approval to enable children with HIV to access recommended ARVs


US FDA’s approval of lopinavir/ritonavir (LPV/r) oral pellets developed by Cipla is a key step for country adoption of this vital WHO-recommended antiretroviral (ARV) for infants and young children with HIV. As DNDi and Cipla continue development of a taste-masked 4-in1 with LPV/r, the new pellets will be part of a large implementation study, funded by UNITAID, in several sub-Saharan African countries. »

Chagas Close-up


“Chagas disease completely changed my life"

For Juan Bautista Corzo Veloza, a 53 year old, father of three,  life is not the same since that day in January 2013 when a stroke left him "dead for three days," he says. He was changing a car tyre while performing his duty as a driver, a job to which he had dedicated himself after retiring from the National Police, when he began to feel a sharp pain in his chest along with a slow loss of consciousness. »

Read the first Newsletter of The Global Chagas Coalition


The Global Chagas Coalition, officially launched in December 2012, is an open, ambitious, collaborative alliance where together, through the sharing of expertise, knowledge, and capacity for action, hopes to achieve the goal of alleviating human suffering caused by Chagas disease and ultimately, controlling Chagas disease once and for all. »

 

Scientific Articles


Science:
Infectious diseases. Overcoming neglect of kinetoplastid diseases »

Antimicrobial Agents and Chemotherapy
:
The limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging »

PLOS Neglected Tropical Diseases:
Multiplex Real-Time PCR Assay Using TaqMan Probes for the Identification of Trypanosoma cruzi DTUs in Biological and Clinical Sample »

PLOS Medicine:
A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance »
Photo credits:
DNDi
EN ESPAÑOL
Punto de Vista: El proyecto FACT: un enfoque exitoso en la resolución de las necesidades de la salud pública »
La Voz del Paciente: "La Enfermedad de Chagas cambió totalmente mi vida"»
Lea la primera edición de la Newsletter de La Coalición Chagas »

EM PORTUGUÊS
Ponto de Vista: Projeto FACT: uma abordagem de sucesso para solucionar necessidades de saúde pública »
A Voz do Paciente: "A doença de Chagas mudou completamente minha vida"»
EVENTS

UPCOMING EVENTS

ECTMIH 2015
Basel, 6-10 September 2015


2nd International HIV/Viral Hepatitis Co-­Infection Meeting
Vancouver, 17-18 July 2015


PAST EVENTS

OpenClinica Conference
Amsterdam,
30 May - 1 June 2015
Presentation
 
JOBS
DNDi IN THE MEDIA
 
 
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2015 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202
Switzerland

Add us to your address book


unsubscribe from this list    update subscription preferences